Prevention of radiocontrast-induced nephropathy

American Journal of Kidney Diseases

Volumn 44, Issue 1, 2004, Pages 12-24

  Asif, Arif ^a   Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

fenoldopam; iso osmolar agents; N acetylcysteine (NAC); Radiocontrast induced nephropathy; ultrafiltration

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CONTRAST MEDIUM; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FENOLDOPAM; FUROSEMIDE; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOTROLAN; MEGLUMINE DIATRIZOATE; MEGLUMINE IOTALAMATE; SODIUM CHLORIDE;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPOTENSION; KIDNEY DISEASE; NONHUMAN; PATIENT CARE; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW;

ACETYLCYSTEINE; ANIMALS; CONTRAST MEDIA; CREATININE; FENOLDOPAM; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE; RENAL DIALYSIS; ULTRAFILTRATION;

EID: 3042852243     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.04.001     Document Type: Review

References (65)

1. Levy E.M., Viscoli C.M., Horwitz R.I. The effects of acute renal failure on mortality. JAMA. 275:1996;1489-1494
2. Heyman S.N., Reichman J., Brezis M. Pathophysiology of radiocontrast nephropathy A role for medullary hypoxia. Invest Radiol. 34:1999;685-691
3. Brezis M., Rosen S. Hypoxia of the renal medulla - Its implications for disease. N Engl J Med. 332:1995;647-656
4. McCullough P.A., Sandberg K.R. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med. 4:(suppl 5):2003;S3-S9
5. Gruberg L., Mehran R., Dangas G., et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv. 52:2001;409-416
6. Marenzi G., Marana I., Lauri G., et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 349:2003;1333-1340
7. McCullough P.A., Wolyn R., Rocher L.L., Levin R.N., O'Neil W.W. Acute renal failure after coronary intervention; Incidence, risk factors, and relationships to mortality. Am J Med. 103:1997;368-375
8. Asif A., Preston R.A., Roth D. Radiocontrast-induced nephropathy. Am J Ther. 10:2003;137-147
9. Singer I., Epstein M. In depth review Potential of dopamine A-1 agonist in the management of acute renal failure. Am J Kidney Dis. 31:1998;743-755
10. Carey R.M., Siragy H.M., Ragsdale N.V., et al. Dopamine-1 and dopamine-2 mechanisms in the control of renal function. Am J Hypertens. 3:(suppl 6):1990;S59-S63
11. Bakris G.L., Lass N.A., Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction A role for dopamine-1 receptors. Kidney Int. 56:1999;206-210
12. Hunter D.W., Chamsuddin A., Bjarnason H., Kowalik K. Preventing contrast-induced nephropathy with fenoldopam. Tech Vasc Interv Radiol. 4:2001;53-56
13. Madyoon H., Croushore L., Weaver D., Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv. 53:2001;341-345
14. Chamsuddin A.A., Kowalik K.J., Bjarnason H., et al. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy. AJR Am J Roentgenol. 179:2002;591-596
15. Kini A.A., Sharma S.K. Managing the high-risk patient Experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med. 2:(suppl 1):2001;S19-S25
16. Tumlin J.A., Wang A., Murray P.T., Mathur V.S. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion A pilot trial in the prevention of contrast nephropathy. Am Heart J. 143:2002;894-903
17. Stone G.W., McCullough P.A., Tumlin J.A., et al. CONTRAST Investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy A randomized controlled trial. JAMA. 290:2003;2284-2291
18. Weisberg L.S., Kurnick P.B., Kurnick B.R. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 45:1994;259-265
19. Aschermann M., Vojacek J., Humhal J., Krupicka P., Holm V., Tesar D. [Early results and complications of percutaneous transluminal coronary angioplasty]. Cor Vasa. 35:1993;80-83
20. Muroya T., Ohe H., Sakai H., et al. A case in which stent insertion is considered to have triggered contrast medium-induced coronary vasospasm. Jpn Circ J. 63:1999;315-318
21. Cohen D.J., Becker E.R., Culler S.D., et al. Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization and coronary angioplasty in 70 catheterization laboratories. Am J Cardiol. 86:2000;595-601
22. Jain D., Schafer U., Dendorfer A., et al. Neurohumoral activation in percutaneous coronary interventions Apropos of ten vasoactive substances during and immediately following coronary rotastenting. Indian Heart J. 53:2001;301-307
23. Rothbaum D.A., Hodes Z.I., Linnemeier T.J., Landin R.J., Ball M.W. Percutaneous transluminal coronary angioplasty for acute myocardial infarction. Cardiol Clin. 7:1989;837-851
24. Mager A., Strasberg B., Rechavia E., et al. Clinical significance and predisposing factors to symptomatic bradycardia and hypotension after percutaneous transluminal coronary angioplasty. Am J Cardiol. 74:1994;1085-1088
25. Whisenant B.K., Baim D.S., Kuntz R.E., Garcia L.A., Ramee S.R., Carrozza J.P. Rheolytic thrombectomy with the Possis AngioJet Technical considerations and initial clinical experience. J Invasive Cardiol. 11:1999;421-426
26. Allison N.L., Dubb J.W., Ziemniak J.A., Alexander F., Stote R.M. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther. 41:1987;282-288
27. Mathur V.S., Swan S.K., Lambrecht L.J., et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med. 27:1999;1832-1837
28. Shusterman N.H., Elliott W.J., White W.B. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 95:1993;161-168
29. Elliott W.J., Weber R.R., Nelson K.S., et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 81:1990;970-977
30. Baud L., Ardaillou R. Reactive oxygen species production and role in the kidney. Am J Physiol. 251:1986;F765-F776
31. Bakris G.L., Lass N., Gaber O. Radiocontrast medium-induced decline in renal function A role for oxygen free radicals. Am J Physiol. 258:1990;F115-F120
32. Baliga R., Ueda N., Walker P.D., Shah S.V. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis. 29:1997;465-477
33. DiMari J., Megyesi J., Udvarhelyi N., Price P., Davis R., Safirstein R.L. N-Acetyl cysteine ameliorates ischemic renal failure. Am J Physiol. 272:1997;F292-F298
34. Safirstein R., Andrade L., Vieira J.M. Acetylcysteine and nephrotoxic effects of radiographic contrast agents - A new use for an old drug. N Engl J Med. 343:2000;210-212
35. Durham J.D., Caputo C., Dokko J., et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 62:2002;2202-2207
36. Tepel M., Van der Giet M., Schwarzfeld C., Laufer U., Liermann D., Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 343:2000;180-184
37. Diaz-Sandoval L.J., Kosowsky B.D., Losordo D.W. Acetylcysteine to prevent angiography-related renal tissue injury (The APART Trial). Am J Cardiol. 89:2002;356-358
38. Briguori C., Manganelli F., Scarpato P., et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 40:2002;298-303
39. Shyu K.G., Cheng J.J., Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 40:2002;1383-1388
40. Kay J., Chow W.H., Chan T.M., et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention A randomized controlled trial. JAMA. 289:2003;553-558
41. Baker C.S., Wragg A., Kumar S., De Palma R., Baker L.R., Knight C.J. A rapid protocol for the prevention of contrast-induced renal dysfunction The RAPPID study. J Am Coll Cardiol. 41:2003;2114-2118
42. Birck R., Krzossok S., Markowetz F., Schnulle P., van der Woude F.J., Braun C. Acetylcysteine for prevention of contrast nephropathy Meta-analysis. Lancet. 362:2003;598-603
43. Goldenberg I., Shechter M., Matetzky S., et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 25:2004;212-218
44. Briguori C., Colombo A., Violante A., et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 25:2004;206-211
45. Katzberg R.W. New and old contrast agents Physiology and nephrotoxicity. Urol Radiol. 10:1988;6-11
46. Katzberg R.W. Urography into the 21st century New contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology. 204:1997;297-312
47. Barrett B.J., Parfrey P.S., Vavasour H.M., et al. Contrast nephropathy in patients with impaired renal function High versus low osmolar media. Kidney Int. 41:1992;1274-1279
48. Rudnick M.R., Goldfarb S., Wexler L., et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients A randomized trial. Kidney Int. 47:1995;254-261
49. Aron N.B., Feinfeld D.A., Peters A.T., Lynn R.I. Acute renal failure associated with ioxaglate, a low-osmolarity radiocontrast agent. Am J Kidney Dis. 13:1989;189-193
50. Liss P. Effects of contrast media on renal microcirculation and oxygen tension. An experimental study in the rat. Acta Radiol. 409:(Suppl):1997;S1-S29
51. Davidson C.J., Hlatky M., Morris K.G., et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med. 110:1989;119-124
52. Harris K.G., Smith T.P., Cragg A.H., Lemke J.H. Nephrotoxicity from contrast material in renal insufficiency Ionic versus nonionic agents. Radiology. 179:1991;849-852
53. Schwab S.J., Hlatky M.A., Pieper K.S., et al. Contrast nephrotoxicity A randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med. 320:1989;149-153
54. Barrett B.J., Carlisle E.J. Meta analysis of the relative nephrotoxicity of high and low-osmolarity iodinated contrast media. Radiology. 188:1993;171-178
55. Grynne B.H., Nossen J.O., Bolstad B., Borch K.W. Main results of the first comparative clinical studies on Visipaque. Acta Radiol. 399:(Suppl):1995;S265-S270
56. Jakobsen J.A. Renal experience with Visipaque. Eur Radiol. 6:(suppl 2):1996;S16-S19
57. Murakami R., Tajima H., Kumazaki T., Yamamoto K. Effect of iodixanol on renal function immediately after abdominal angiography. Clinical comparison with iomeprol and ioxaglate. Acta Radiol. 39:1998;368-371
58. Carraro M., Malalan F., Antonione R., et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency A double-blind, randomized clinical trial. Eur Radiol. 8:1998;144-147
59. Chalmers N., Jackson R.W. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol. 72:1999;701-703
60. Davidson C.J., Laskey W.K., Hermiller J.B., et al. Randomized trial of contrast media utilization in high-risk PTCA The COURT trial. Circulation. 101:2000;2172-2177
61. Aspelin P., Aubry P., Fransson S.G., Strasser R., Willenbrock R., Berg K.J. Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 348:2003;491-499
62. Cigarroa R.G., Lange R.A., Williams R.H., Hillis L.D. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 86:1989;649-652
63. Vogt B., Ferrari P., Schonholzer C., et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med. 111:2001;692-698
64. Frank H., Werner D., Lorusso V., et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol. 60:2003;176-182
65. Mueller C., Buerkle G., Buettner H.J., et al. Prevention of contrast media-associated nephropathy; Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 162:2002;329-336